The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Open accessAbstract
BACKGROUND: Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis. METHODS: Of a total of 942 patients, 627 were randomly assigned to receive natalizumab (at a dose of 300 mg) and 315 to receive placebo by intravenous infusion every four weeks for more than two years. The primary end points were the rate of clinical relapse at one year and the rate of sustained progression of disability, as measured by the Expanded Disability Status Scale, at two years. RESULTS: Natalizumab reduced the risk of sustained progression of disability by 42 percent over two years (hazard ratio, 0.58; 95 percent confidence interval, 0.43 to 0.77; P<0.001). The cumulative probability of progression (on the basis of Kaplan-Meier analysis) was 17 percent in the natalizumab group and 29 percent in the placebo group. Natalizumab reduced the rate of clinical relapse at one year by 68 percent (P<0.001) and led to an 83 percent reduction in the accumulation of new or enlarging hyperintense lesions, as detected by T2-weighted magnetic resonance imaging (MRI), over two years (mean numbers of lesions, 1.9 with natalizumab and 11.0 with placebo; P<0.001). There were 92 percent fewer lesions (as detected by gadolinium-enhanced MRI) in the natalizumab group than in the placebo group at both one and two years (P<0.001). The adverse events that were significantly more frequent in the natalizumab group than in the placebo group were fatigue (27 percent vs. 21 percent, P=0.048) and allergic reaction (9 percent vs. 4 percent, P=0.012). Hypersensitivity reactions of any kind occurred in 25 patients receiving natalizumab (4 percent), and serious hypersensitivity reactions occurred in 8 patients (1 percent). CONCLUSIONS: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis. Adhesion-molecule inhibitors hold promise as an effective treatment for relapsing multiple sclerosis. (ClinicalTrials.gov number, NCT00027300.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Self-citationIntramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Elices, M. J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M. E., & Lobb, R. R. (1990) · Cell · doi:10.1016/0092-8674(90)90661-w · Cited by 1,808
Cited by
Items 101–141 of 141
Natalizumab for Multiple Sclerosis
Ransohoff, R. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071462 · Cited by 253
Giovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., & Greenberg, S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70023-0 · Cited by 252
Self-citationThe many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
Morris, G., & Berk, M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0310-y · Cited by 245
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Oligodendrocyte death results in immune-mediated CNS demyelination
Traka, M., Podojil, J. R., McCarthy, D. P., Miller, S. D., & Popko, B. (2016) · Nature Neuroscience · doi:10.1038/nn.4193 · Cited by 195
Health‐related quality of life in multiple sclerosis: effects of natalizumab
Rudick, R. A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P. A., Confavreux, C., Galetta, S. L., Giovannoni, G., Havrdova, E., Kappos, L., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21163 · Cited by 195
Self-citationInflammation-related plasma and CSF biomarkers for multiple sclerosis
Huang, J., Khademi, M., Fugger, L., Lindhe, Ö., Novakova, L., Axelsson, M., Malmeström, C., Constantinescu, C., Lycke, J., Piehl, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912839117 · Cited by 194
Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?
Mayne, K., White, J. A., McMurran, C. E., Rivera, F. J., & de la Fuente, A. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572090 · Cited by 167
Pericytes regulate vascular immune homeostasis in the CNS
Török, O., Schreiner, B., Schaffenrath, J., Tsai, H.-C., Maheshwari, U., Stifter, S. A., Welsh, C., Amorim, A., Sridhar, S., Utz, S. G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016587118 · Cited by 166
Translational value of choroid plexus imaging for tracking neuroinflammation in mice and humans
Fleischer, V., Gonzalez-Escamilla, G., Ciolac, D., Albrecht, P., Küry, P., Gruchot, J., Dietrich, M., Hecker, C., Müntefering, T., Bock, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025000118 · Cited by 152
Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis
Lengfeld, J. E., Lutz, S. E., Smith, J. R., Diaconu, C., Scott, C., Kofman, S. B., Choi, C., Walsh, C. M., Raine, C. S., Agalliu, I., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609905114 · Cited by 152
Wu, W.-F., Tan, X.-J., Dai, Y.-B., Krishnan, V., Warner, M., & Gustafsson, J.-Å. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300313110 · Cited by 149
Safavi, F., Nourbakhsh, B., & Azimi, A. R. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102195 · Cited by 140
Patejdl, R., Penner, I. K., Noack, T. K., & Zettl, U. K. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.11.005 · Cited by 141
Larochelle, C., Cayrol, R., Kebir, H., Alvarez, J. I., Lécuyer, M.-A., Ifergan, I., Viel, É., Bourbonnière, L., Beauseigle, D., Terouz, S., et al. (2012) · Brain · doi:10.1093/brain/aws212 · Cited by 145
Kumar, P., Lim, A., Hazirah, S. N., Chua, C. J. H., Ngoh, A., Poh, S. L., Yeo, T. H., Lim, J., Ling, S., Sutamam, N. B., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01095-5 · Cited by 142
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS
Flanagan, K., Fitzgerald, K., Baker, J., Regnstrom, K., Gardai, S., Bard, F., Mocci, S., Seto, P., You, M., Larochelle, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040443 · Cited by 134
Swanson, P. A., Hart, G. T., Russo, M. V., Nayak, D., Yazew, T., Peña, M., Khan, S. M., Janse, C. J., Pierce, S. K., & McGavern, D. B. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1006022 · Cited by 125
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Stüve, O., & Bennett, J. L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00003.x · Cited by 123
Will Rogers phenomenon in multiple sclerosis
Sormani, M. P., Tintorè, M., Rovaris, M., Rovira, A., Vidal, X., Bruzzi, P., Filippi, M., & Montalban, X. (2008) · Annals of Neurology · doi:10.1002/ana.21464 · Cited by 104
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients
Eggers, E. L., Michel, B. A., Wu, H., Wang, S.-Z., Bevan, C. J., Abounasr, A., Pierson, N. S., Bischof, A., Kazer, M., Leitner, E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92724 · Cited by 93
Kooij, G., Mizee, M. R., van Horssen, J., Reijerkerk, A., Witte, M. E., Drexhage, J. A. R., van der Pol, S. M. A., van het Hof, B., Scheffer, G., Scheper, R., et al. (2011) · Brain · doi:10.1093/brain/awq330 · Cited by 90
Immunomodulatory therapies delay disease progression in multiple sclerosis
Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., D’Onghia, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458512445941 · Cited by 71
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
Age-related tumor growth in mice is related to integrin α 4 in CD8+ T cells
Oh, J., Magnuson, A., Benoist, C., Pittet, M. J., & Weissleder, R. (2018) · JCI Insight · doi:10.1172/jci.insight.122961 · Cited by 51
Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328122de1b · Cited by 46
Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy
Bermel, R. A., Rae-Grant, A. D., & Fox, R. J. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510377334 · Cited by 46
Estin, M. L., Thompson, S. B., Traxinger, B., Fisher, M. H., Friedman, R. S., & Jacobelli, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701886114 · Cited by 45
Interferon-β1bin multiple sclerosis
Buttmann, M., & Rieckmann, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.3.227 · Cited by 43
Tilling, K., Lawton, M., Robertson, N., Tremlett, H., Zhu, F., Harding, K., Oger, J., & Ben-Shlomo, Y. (2016) · Health Technology Assessment · doi:10.3310/hta20810 · Cited by 43
Khan, R. S., Dine, K., Luna, E., Ahlem, C., & Shindler, K. S. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-14672 · Cited by 33
Consensus guidelines for the diagnosis and treatment of multiple sclerosis
Yamout, B., Alroughani, R., Al-Jumah, M., Khoury, S., Abouzeid, N., Dahdaleh, M., Alsharoqi, I., Inshasi, J., Hashem, S., Zakaria, M., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.787979 · Cited by 25
Integrin Signaling in the Central Nervous System in Animals and Human Brain Diseases
Ikeshima-Kataoka, H., Sugimoto, C., & Tsubokawa, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031435 · Cited by 24
Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Islam, M. A., Kundu, S., & Hassan, R. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200306092556 · Cited by 21
Glial cells as therapeutic targets in progressive multiple sclerosis
Wilbanks, B., Maher, L., & Rodriguez, M. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1614443 · Cited by 17
Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials?
Mateen, F. J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.680912 · Cited by 15
Duarte, J., Carrié, N., Oliveira, V. G., Almeida, C., Agua-Doce, A., Rodrigues, L., Simas, J. P., Mars, L. T., & Graca, L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201269 · Cited by 13
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Insights and challenges on animal models for progressive multiple sclerosis
Nalepa, I. F., Haahr, N. O., Bekiaris, V., Jakobsen, M. R., Asuni, A. A., & Benmamar-Badel, A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03805-3 · Cited by 1
Metadata
- Authors
- Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., & Sandrock, A. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-02
- Volume
- 354
- Issue
- 9
- Pages
- 899-910
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103758700
- Cited by
- 3,386
- References
- 33
- FWCI
- 110.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.